Understanding the role of non-coding RNA (ncRNA) in stent restenosis

Liu, Shaoyan; Yang, Yanyan; Jiang, Shaoyan; Tang, Ningning; Tian, Jiawei; Ponnusamy, Murugavel; Tariq, Muhammad; Lian, Zhexun; Hui, Xin; Yu, Tao

doi:10.1016/j.atherosclerosis.2018.03.036

Cited by 50 publications

(37 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNA (miRNAs) are non‐coding RNAs, mainly mediating gene expression at posttranscriptional levels . Hundreds of miRNAs have been found.…”

Section: Introductionmentioning

confidence: 99%

“…MicroRNA (miRNAs) are non-coding RNAs, mainly mediating gene expression at posttranscriptional levels. 12,13 Hundreds of miRNAs have been found. In the human genome, miRNAs regulate protein encoding genes at a rate of approximately 1:3, controlling cell apoptosis, proliferation, differentiation, metabolism, individual development and tumorigenesis, and drug resistance.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

Jin

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe five‐year survival rate of non‐small cell lung cancer (NSCLC) patients is very low. MiR‐873 is involved in the growth, metastasis, and differentiation of tumors. Herein, we determined the target gene and influence of miR‐873 in NSCLC.MethodsMiRanda and Targetscan websites were used to predict the target gene of miR‐873 in NSCLC. Luciferase activity was examined using a dual luciferase reporter gene assay kit. The viability, tube formation, and proliferation of cells were analyzed by cell counting kit‐8, angiogenic analysis, and flow cytometry, respectively. The levels of miR‐873 and GLI1 were evaluated using quantitative real‐time PCR and Western blot assays.ResultsLow levels of GLI1 and high levels of miR‐873 were observed in an NSCLC cell line (PC9) highly sensitive to EGFR‐tyrosine kinase inhibitors. There was a negative correlation between miR‐873 and GLI1 expression in PC9 and PC9/GR cells. The inhibition of miR‐873 enhanced GLI1 levels. MiR‐873 expression was inhibited by gefitinib. Gefitinib markedly reduced the viability, tube formation, and cell number in PC9 cells. However, suppression of miR‐873 enhanced the resistance and knockdown of GLI1 enhanced the sensitivity of PC9 cells to gefitinib.Conclusions GLI1 is a target gene of miR‐873 in NSCLC. The inhibition of miR‐873 increased gefitinib resistance of NSCLC cells via the upregulation of GLI1. These results indicate that miR‐873‐GLI1 signaling is involved in gefitinib resistance in NSCLC.

show abstract

“…MicroRNA (miRNAs) are non‐coding RNAs, mainly mediating gene expression at posttranscriptional levels . Hundreds of miRNAs have been found.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

Jin

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…VSMCs express miRNAs, and there is a causal link between miRNAs such miR-21, miR-125b, miR-133a, miR-136, miR-143/145, miR-1, and miR-206 and the pathogenesis of vascular disorders in cardiovascular disease with diabetes mellitus [27]. It is important that miRNAs such as miRNA-143/-145, miR-133, miR-125a-5p, miR-23b, miR-638, miR-663, miR-21, miR-100, miR-143, and miR-145 can regulate VMSC function, and miR-126-3p, miR-126-5p, miR-92a, miR-221, and miR-222 can also regulate endothelial cell function [28,29].…”

Section: Regulation Of Mirnas In Chdmentioning

confidence: 99%

Advances in Research on the circRNA‐miRNA‐mRNA Network in Coronary Heart Disease Treated with Traditional Chinese Medicine

Lin

Chen

Zhao

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

There has been an increase in morbidity and mortality related to coronary heart disease (CHD) in China in recent years. Numerous clinical experiences and studies have shown that traditional Chinese medicine (TCM) plays an important role in the prevention, treatment, and prognosis of CHD. However, the mechanism of TCM in the treatment of CHD has not yet been elucidated. The circRNA-miRNA-mRNA network consists of miRNA that is competitively bound by circRNA, and miRNA regulates the transcription level of mRNA. Through literature review, we found that the circRNA-miRNA-mRNA network acts to contribute to certain effects to CHD such as myocardial hypertrophy, myocardial fibrosis, and heart failure. TCM contains constituents that act against CHD by antiatherosclerosis and apoptosis inhibition action, cardiac and cardiomyocyte protection, and these components also promote cell growth and protection of the vascular system by regulating miRNAs. Therefore, we consider that the circRNA-miRNA-mRNA network may be a new regulatory mechanism for the effective treatment of CHD by TCM.

show abstract

“…Under normal situations, VSMCs keep a resting status termed as contractile phenotype in the tunica media, but they change into the unchecked synthetic phenotype and then proliferate and mobilize into the subendothelial layer, thereby leading to intimal thickening, in response to diverse stimuli such as inflammatory cytokines and stress damage. After switching into the synthetic state, VSMCs possess lessened levels of differentiation biomarkers including α-SMA, SM22α, and SM-MHC, except for exhibiting enhanced growth and migration capabilities ( Bennett et al, 2016 ; Durgin and Straub, 2018 ; Liu et al, 2018 ). Che et al (2010) reported that the expression of α-SMA and SM-MHC in VSMCs was elevated after co-administration of VSMCs with different concentrations of SBP.…”

Section: Protective Mechanisms Of Sbpmentioning

confidence: 99%

Shexiang Baoxin Pill, Derived From the Traditional Chinese Medicine, Provides Protective Roles Against Cardiovascular Diseases

et al. 2018

View full text Add to dashboard Cite

Shexiang Baoxin Pill (SBP), derived from the traditional Chinese medicine, has been broadly applied for the treatment of cardiovascular diseases including coronary heart disease, heart failure, and hypertension in East Asia for decades. Emerging pharmacological studies have revealed that SBP displays pleiotropic roles in protecting the cardiovascular system, as seen by the promotion of angiogenesis, amelioration of inflammation, improvement of endothelium dysfunction, mitigation of dyslipidemia, repression of vascular smooth muscle cell proliferation, and migration and restraint of cardiac remodeling. In terms of clinical practice, the clinical trials and meta-analyses have proved the efficacy and safety of SBP. In this review, we, for the first time, systematically summarize the cardioprotective effects and underlying mechanisms of SBP and provide novel insights into future research directions of SBP based on the experimental and clinical perspectives.

show abstract

Understanding the role of non-coding RNA (ncRNA) in stent restenosis

Cited by 50 publications

References 81 publications

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

Advances in Research on the circRNA‐miRNA‐mRNA Network in Coronary Heart Disease Treated with Traditional Chinese Medicine

Shexiang Baoxin Pill, Derived From the Traditional Chinese Medicine, Provides Protective Roles Against Cardiovascular Diseases

Contact Info

Product

Resources

About